Zacks Research Issues Negative Estimate for Bruker Earnings

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Zacks Research dropped their Q3 2025 earnings estimates for Bruker in a research note issued on Monday, April 7th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $0.69 for the quarter, down from their prior forecast of $0.70. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q2 2026 earnings at $0.69 EPS, FY2026 earnings at $3.09 EPS and Q1 2027 earnings at $0.66 EPS.

Several other research analysts have also recently weighed in on BRKR. Guggenheim reiterated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Barclays lowered their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a “buy” rating on the stock in a report on Monday. Bank of America increased their price objective on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, Stifel Nicolaus cut their target price on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average price target of $68.00.

Bruker Price Performance

Shares of BRKR opened at $38.70 on Tuesday. The stock has a 50 day simple moving average of $48.29 and a 200 day simple moving average of $55.79. Bruker has a 52-week low of $34.10 and a 52-week high of $91.34. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The firm has a market capitalization of $5.87 billion, a PE ratio of 50.92, a P/E/G ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Monday, March 17th. Bruker’s dividend payout ratio is 26.32%.

Hedge Funds Weigh In On Bruker

Several institutional investors and hedge funds have recently modified their holdings of BRKR. London Co. of Virginia boosted its holdings in shares of Bruker by 78.4% during the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company’s stock worth $245,820,000 after buying an additional 1,843,294 shares during the period. Sculptor Capital LP grew its position in shares of Bruker by 484.1% in the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company’s stock valued at $100,476,000 after purchasing an additional 1,420,569 shares during the last quarter. FIL Ltd grew its position in shares of Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company’s stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. Steadfast Capital Management LP bought a new position in shares of Bruker during the fourth quarter worth approximately $63,997,000. Finally, Norges Bank acquired a new stake in Bruker during the 4th quarter worth approximately $63,378,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.